

## SEQUENCE LISTING

&lt;110&gt; OUI MET et al.

&lt;120&gt; Novel membrane-bound metalloprotease NEP II and the use thereof for screening inhibitors useful in therapy

&lt;130&gt; P06910US0/BAS

&lt;140&gt;

&lt;141&gt;

&lt;150&gt; PCT/FR99/00807

&lt;151&gt; 1999-04-07

&lt;150&gt; FR/9804389

&lt;151&gt; 1998-04-08

&lt;160&gt; 29

&lt;170&gt; PatentIn Ver. 2.1

&lt;210&gt; 1

&lt;211&gt; 2765

&lt;212&gt; DNA

&lt;213&gt; Rattus rattus

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (107) ... (2428)

&lt;400&gt; 1

gcaaagcact agcttcagtg tgctcaaggc atccaagctc cagctgcctc cctcctggcc 60

ctggccctgg gtgctcagct gtgtgccttc caccagaac cggctg atg ggg aag 115  
Met Gly Lys

1

tcg gag agc tca gtg ggg atg atg gag aga gcg gac aac tgt ggg agg 163

Ser Glu Ser Ser Val Gly Met Met Glu Arg Ala Asp Asn Cys Gly Arg

5

10

15

agg cgc cta ggc ttc gtg gag tgt ggg ctg ctg gta ctg ctg aca ctg 211

Arg Arg Leu Gly Phe Val Glu Cys Gly Leu Leu Val Leu Leu Thr Leu

20

25

30

35

ctg ttg atg gga gcc ata gtg act ctg ggt gtc ttc tac agc ata ggg 259

Leu Leu Met Gly Ala Ile Val Thr Leu Gly Val Phe Tyr Ser Ile Gly

40

45

50

aag cag ctg ccc ctc tta aat agc ctg ctg cac gtc tcc cgg cat gag 307

Lys Gln Leu Pro Leu Leu Asn Ser Leu Leu His Val Ser Arg His Glu

55

60

65

agg acg gtt gta aaa cga gtc ctc aga gat tca tcg cag aag agt gac 355



295								300				305				
aca	cat	ctg	gcc	aac	gcc	acg	gtc	ccc	cag	gag	aaa	agg	cat	gat	gtc	1075
Thr	His	Leu	Ala	Asn	Ala	Thr	Val	Pro	Gln	Glu	Lys	Arg	His	Asp	Val	
		310					315					320				
acc	gcc	ctg	tat	cac	cga	atg	ggc	ctg	gag	gag	ctg	cag	gaa	agg	ttt	1123
Thr	Ala	Leu	Tyr	His	Arg	Met	Gly	Leu	Glu	Glu	Leu	Gln	Glu	Arg	Phe	
		325				330					335					
ggc	ctg	aag	ggg	ttt	aac	tgg	act	ctc	ttc	ata	caa	aac	gtg	ctg	tct	1171
Gly	Leu	Lys	Gly	Phe	Asn	Trp	Thr	Leu	Phe	Ile	Gln	Asn	Val	Leu	Ser	
		340			345					350					355	
tct	gtg	caa	gtt	gag	ctg	ctc	cgc	aat	gag	gag	gtg	gtg	gtc	tat	ggc	1219
Ser	Val	Gln	Val	Glu	Leu	Leu	Pro	Asn	Glu	Glu	Val	Val	Val	Tyr	Gly	
				360						365				370		
atc	ccc	tac	ctg	gag	aac	ctt	gag	gag	atc	att	gac	gtc	ttc	cca	gca	1267
Ile	Pro	Tyr	Leu	Glu	Asn	Leu	Glu	Glu	Ile	Ile	Asp	Val	Phe	Pro	Ala	
			375				380						385			
cag	acc	ttg	caa	aac	tac	ctg	gtg	tgg	cgc	ctg	gtg	cta	gat	cgc	atc	1315
Gln	Thr	Leu	Gln	Asn	Tyr	Leu	Val	Trp	Arg	Leu	Val	Leu	Asp	Arg	Ile	
		390					395					400				
ggc	agc	ctg	agc	cag	aga	ttc	aaa	gaa	gcg	cgt	gtg	gac	tac	cgc	aag	1363
Gly	Ser	Leu	Ser	Gln	Arg	Phe	Lys	Glu	Ala	Arg	Val	Asp	Tyr	Arg	Lys	
		405				410					415					
gcg	ctg	tac	ggc	aca	acc	atg	gag	gaa	gta	cgc	tgg	cgg	gag	tgt	gtc	1411
Ala	Leu	Tyr	Gly	Thr	Thr	Met	Glu	Glu	Val	Arg	Trp	Arg	Glu	Cys	Val	
		420			425					430				435		
agc	tat	gtc	aac	agc	aac	atg	gag	agt	gcc	gtg	ggc	tcc	ctc	tac	atc	1459
Ser	Tyr	Val	Asn	Ser	Asn	Met	Glu	Ser	Ala	Val	Gly	Ser	Leu	Tyr	Ile	
				440					445					450		
aag	cgg	gcc	ttc	tcc	aag	gac	agc	aag	agc	ata	gtc	agt	gag	ctt	atc	1507
Lys	Arg	Ala	Phe	Ser	Lys	Asp	Ser	Lys	Ser	Ile	Val	Ser	Glu	Leu	Ile	
		455					460						465			
gag	aag	ata	cgg	tcc	gtg	ttt	gtg	gat	aac	ctg	gac	gag	ttg	aac	tgg	1555
Glu	Lys	Ile	Arg	Ser	Val	Phe	Val	Asp	Asn	Leu	Asp	Glu	Leu	Asn	Trp	
		470				475						480				
atg	gat	gag	gaa	tcc	aag	aaa	aag	gcc	cag	gaa	aag	gcc	ttg	aat	atc	1603
Met	Asp	Glu	Glu	Ser	Lys	Lys	Lys	Ala	Gln	Glu	Lys	Ala	Leu	Asn	Ile	
		485				490					495					
cgg	gaa	cag	atc	ggc	tac	cct	gac	tac	att	ttg	gaa	gac	aat	aac	aga	1651
Arg	Glu	Gln	Ile	Gly	Tyr	Pro	Asp	Tyr	Ile	Leu	Glu	Asp	Asn	Asn	Arg	
		500			505					510					515	
cac	ctg	gat	gag	gaa	tac	tcc	agt	ctg	act	ttc	tca	gag	gac	ctg	tat	1699
His	Leu	Asp	Glu	Glu	Tyr	Ser	Ser	Leu	Thr	Phe	Ser	Glu	Asp	Leu	Tyr	
				520					525					530		

ttt	gag	aac	ggg	ctt	cag	aac	ctc	aag	aac	aat	gcc	caa	agg	agc	ctc	1747
Phe	Glu	Asn	Gly	Leu	Gln	Asn	Leu	Lys	Asn	Asn	Ala	Gln	Arg	Ser	Leu	
			535					540					545			
aag	aaa	ctt	cgg	gaa	aag	gtg	gac	cag	aat	ctc	tgg	atc	att	ggg	gct	1795
Lys	Lys	Leu	Arg	Glu	Lys	Val	Asp	Gln	Asn	Leu	Trp	Ile	Ile	Gly	Ala	
		550					555					560				
gca	gtg	gtc	aat	gca	ttc	tac	tcc	cca	aac	aga	aac	ctg	atc	gtc	ttt	1843
Ala	Val	Val	Asn	Ala	Phe	Tyr	Ser	Pro	Asn	Arg	Asn	Leu	Ile	Val	Phe	
		565				570					575					
cca	gcg	ggg	atc	ctc	cag	cca	ccc	ttc	ttc	agc	aag	gac	caa	cca	cag	1891
Pro	Ala	Gly	Ile	Leu	Gln	Pro	Pro	Phe	Phe	Ser	Lys	Asp	Gln	Pro	Gln	
580					585					590					595	
gcc	ttg	aat	ttc	ggg	ggc	atc	ggg	atg	gtg	att	gga	cac	gag	atc	aca	1939
Ala	Leu	Asn	Phe	Gly	Gly	Ile	Gly	Met	Val	Ile	Gly	His	Glu	Ile	Thr	
			600					605						610		
cac	ggc	ttt	gat	gat	aac	ggg	cgg	aac	ttt	gac	aag	aat	ggc	aac	atg	1987
His	Gly	Phe	Asp	Asp	Asn	Gly	Arg	Asn	Phe	Asp	Lys	Asn	Gly	Asn	Met	
			615				620						625			
ctg	gac	tgg	tgg	agc	aac	ttc	tcg	gcc	cgg	cac	ttc	cga	cag	cag	tca	2035
Leu	Asp	Trp	Trp	Ser	Asn	Phe	Ser	Ala	Arg	His	Phe	Arg	Gln	Gln	Ser	
		630					635					640				
cag	tgt	atg	att	tat	cag	tac	agc	aac	ttc	tct	tgg	gaa	cta	gca	gac	2083
Gln	Cys	Met	Ile	Tyr	Gln	Tyr	Ser	Asn	Phe	Ser	Trp	Glu	Leu	Ala	Asp	
		645				650					655					
aac	cag	aat	gtg	aac	gga	ttc	agc	acc	ctc	ggg	gag	aac	atc	gcc	gac	2131
Asn	Gln	Asn	Val	Asn	Gly	Phe	Ser	Thr	Leu	Gly	Glu	Asn	Ile	Ala	Asp	
660					665					670					675	
aac	ggc	ggg	gtg	cgg	cag	gca	tac	aag	gct	tac	cta	cag	tgg	cta	gct	2179
Asn	Gly	Gly	Val	Arg	Gln	Ala	Tyr	Lys	Ala	Tyr	Leu	Gln	Trp	Leu	Ala	
				680				685						690		
gaa	ggc	ggc	aga	gac	cag	aga	ctg	ccg	gga	ctg	aac	ctg	acc	tat	gct	2227
Glu	Gly	Gly	Arg	Asp	Gln	Arg	Leu	Pro	Gly	Leu	Asn	Leu	Thr	Tyr	Ala	
			695				700					705				
cag	ctt	ttc	ttc	att	aac	tat	gcc	cag	gtg	tgg	tgt	ggg	tcc	tac	agg	2275
Gln	Leu	Phe	Phe	Ile	Asn	Tyr	Ala	Gln	Val	Trp	Cys	Gly	Ser	Tyr	Arg	
		710					715					720				
ccg	gag	ttc	gcc	atc	cag	tcc	atc	aag	aca	gat	gtc	cac	agt	cct	ctt	2323
Pro	Glu	Phe	Ala	Ile	Gln	Ser	Ile	Lys	Thr	Asp	Val	His	Ser	Pro	Leu	
		725				730										



175

Glu Leu Ile Glu Lys Ile Arg Ser Val Phe Val Asp Asn Leu Asp Glu

480

Asn Arg Cys Arg Ile Trp

1. The first part of the report is a general statement of the purpose of the study.

**SECRET**

```
<210> 5
<211> 20
<212> DNA
<213> artificial sequence
```





21

22

22

20

20

20.

<220>  
<223> oligonucleotide

20

<220>  
<223> oligonucleotide

21

<220>  
<223> oligonucleotide

21

<220>  
<223> oligonucleotide

19

<220>  
<223> oligonucleotide

19

20

18

22

26

1. The first part of the report is a general statement of the purpose of the study.

<400> 26  
gagcagctct tcttcac

18

<210> 27  
<211> 22  
<212> DNA  
<213> artificial sequence

<220>  
<223> oligonucleotide

<400> 27  
ctccaccaat ccatcatggt gc

22

```
<210> 28
<211> 6
<212> PRT
<213> artificial sequence
```

<220>  
<223> protein sequence corresponding to the oligonucleotide probe SEQ ID No. 22

<400> 28  
Glu Ile Thr His Phe Asp  
1 5

```
<210> 29
<211> 6
<212> PRT
<213> artificial sequence
```

<220>  
<223> protein sequence corresponding to the oligonucleotide probe SEQ ID No. 23

<400> 29  
Gln Val Trp Cys Gly Ser  
1 5

1. The first part of the document is a list of names and addresses, which appears to be a directory or a list of subscribers. The names are written in a cursive script, and the addresses are listed below them.

<120> Novel membrane-bound metalloprotease NEP II and the use thereof for screening inhibitors useful in therapy

<140>

<141>

<150> PCT/FR99/00807

<151> 1999-04-07

<150> FR/9804389

<151> 1998-04-08

<160> 29

&lt;170&gt; PatentIn Ver. 2.1

 $\langle 210 \rangle$  1

<211> 2765

<212> DNA

<213> Rattus rattus

<220>

&lt;221&gt; CDS

 $\langle 222 \rangle$  (107) ... (2428)

<400> 1

GCAAAGCACT AGCTTCAGTG TGCTCAAGGC ATCCAAGCTC CAGCTGCCTC CCTCCTGGCC 60

CTGGCCCTGG GTGCTCAGCT GTGTGCCTTC CACCCAGAAC CGGCTG ATG GGG AAG 115

Met Gly Lys

1

TCG GAG AGC TCA GTG GGG ATG ATG GAG AGA GCG GAC AAC TGT GGG AGG 163

Ser Glu Ser Ser Val Gly Met Met Glu Arg Ala Asp Asn Cys Gly Arg

□

10

15

AGG CGC CTA GGC TTC GTG GAG TGT GGG CTG CTG GTA CTG CTG ACA CTG 211

Arg Arg Leu Gly Phe Val Glu Cys Gly Leu Leu Val Leu Leu Thr Leu

20

25

30

35

CTG TTG ATG GGA GCC ATA GTG ACT CTG GGT GTC TTC TAC AGC ATA GGG 259

Leu Leu Met Gly Ala Ile Val Thr Leu Gly Val Phe Tyr Ser Ile Gly

40

45

50

AAG CAG CTG CCC CTC TTA AAT AGC CTG CTG CAC GTC TCC CGG CAT GAG 307

Lys Gln Leu Pro Leu Leu Asn Ser Leu Leu His Val Ser Arg His Glu

55

60

65

AGG ACG GTT GTA AAA CGA GTC CTC AGA GAT TCA TCG CAG AAG AGT GAC 355

Arg Thr Val Val Lys Arg Val Leu Arg Asp Ser Ser Gln Lys Ser Asp

70

75

80

ATC Ile	TGT Cys 85	ACT Thr	ACC Thr	CCA Pro	AGC Ser	TGC Cys 90	GTG Val	ATA Ile	GCA Ala	GCT Ala	GCC Ala 95	AGA Arg	ATC Ile	CTC Leu	CAG Gln	403
AAC Asn 100	ATG Met	GAC Asp	CAG Gln	TCA Ser	AAG Lys 105	AAA Lys	CCC Pro	TGC Cys	GAC Asp	AAC Asn 110	TTC Phe	TAT Tyr	CAG Gln	TAT Tyr	GCT Ala 115	451
TGC Cys	GGA Gly	GGC Gly	TGG Trp	CTA Leu 120	CGG Arg	CAC His	CAT His	GTG Val	ATC Ile 125	CCC Pro	GAG Glu	ACC Thr	AAC Asn	TCC Ser 130	AGA Arg	499
TAC Tyr	AGC Ser	GTC Val	TTT Phe 135	GAC Asp	ATC Ile	CTT Leu	CGG Arg	GAT Asp 140	GAG Glu	CTG Leu	GAG Glu	GTC Val	ATC Ile	CTC Leu	AAA Lys	547
GGG Gly	GTG Val 150	CTG Leu	GAG Glu	GAT Asp	TCC Ser	TCT Ser	GTC Val 155	CAG Gln	CAC His	CGC Arg	CCA Pro 160	GCT Ala	GTG Val	GAG Glu	AAG Lys	595
GCC Ala 165	AAG Lys	ACA Thr	CTG Leu	TAC Tyr	CGC Arg	TCC Ser 170	TGC Cys	ATG Met	AAC Asn	CAG Gln 175	AGT Ser	GTG Val	ATA Ile	GAG Glu	AAG Lys	643
AGA Arg 180	GAC Asp	TCT Ser	GAG Glu	CCC Pro	CTG Leu 185	CTG Leu	AAC Asn	GTC Val	TTA Leu	GAT Asp 190	ATG Met	ATA Ile	GGA Gly	GGT Gly	TGG Trp 195	691
CCT Pro	GTA Val	GCC Ala	ATG Met	GAC Asp 200	AAG Lys	TGG Trp	AAT Asn	GAG Glu	ACC Thr 205	ATG Met	GGC Gly	CCC Pro	AAG Lys	TGG Trp 210	GAA Glu	739
CTG Leu	GAG Glu	CGG Arg	CAG Gln 215	TTG Leu	GCT Ala	GTG Val	TTG Leu	AAC Asn 220	TCG Ser	CAG Gln	TTC Phe	AAC Asn	AGG Arg 225	CGC Arg	GTC Val	787
CTC Leu	ATC Ile	GAC Asp 230	CTC Leu	TTC Phe	ATC Ile	TGG Trp	AAT Asn 235	GAT Asp	GAC Asp	CAG Gln	AAC Asn 240	TCC Ser	AGC Ser	CGG Arg	CAC His	835
GTC Val	ATC Ile 245	TAC Tyr	ATA Ile	GAC Asp	CAG Gln	CCC Pro 250	ACC Thr	TTG Leu	GGC Gly	ATG Met 255	CCC Pro	TCC Ser	CGG Arg	GAG Glu	TAC Tyr	883
TAT Tyr 260	TTC Phe	AAG Lys	GAA Glu	GAC Asp	AGC Ser 265	CAC His	CGG Arg	GTA Val	CGG Arg	GAA Glu 270	GCC Ala	TAC Tyr	CTG Leu	CAG Gln	TTC Phe 275	931
ATG Met	ACA Thr	TCA Ser	GTG Val	GCC Ala 280	ACT Thr	ATG Met	CTG Leu	AGG Arg	AGA Arg 285	GAC Asp	CTG Leu	AAC Asn	CTG Leu	CCC Pro 290	GGG Gly	979
GAG Glu	ACC Thr	GAT Asp	TTG Leu 295	GTG Val	CAG Gln	GAG Glu	GAA Glu	ATG Met 300	GCA Ala	CAG Gln	GTG Val	CTG Leu	CAT His 305	CTG Leu	GAG Glu	1027
ACA Ile	CAT Ile	CTG Ile	GCC Ala	AAC Asn	GCC Ala	ACG Glu	GTC Val	CCC Ala	CAG Ala	GAG Ala	AAA Ala	AGG Ala	CAT Ala	GAT Ala	GTC Ala	1075











495

Asn Arg Cys Arg Ile Trp  
770

<210> 3

<211> 327  
 <212> DNA  
 <213> Homo sapiens

<400> 3  
 GGGCACGAGA TCACGCACGG CTTTGATGAC AATGGCCGGA ACTTCGACAA GAATGGCAAC 60  
 ATGATGGATT GGTGGAGTAA CTTCTCCACC CAGCACTTCC GGGAGCAGTC AGAGTGCATG 120  
 ATCTACCAGT ACGGCAACTA CTCCTGGGAC CTGGCAGACG AACAGAACGT GAACGGATTC 180  
 AACACCCTTG GGGAAAACAT TGCTGACAAC GGAGGGGTGC GGCAAGCCTA TAAGGCCTAC 240  
 CTCAAGTGGA TGGCAGAGGG TGGCAAGGAC CAGCAGCTGC CCGGCCTGGA TCTCACCCAT 300  
 GAGCAGCTCT TCTTCATCAA CTATGCC 327

<210> 4  
 <211> 116  
 <212> PRT  
 <213> Homo sapiens

<400> 4  
 Gly His Glu Ile Thr His Gly Phe Asp Asp Asn Gly Arg Asn Phe Asp  
 1 5 10 15  
 Lys Asn Gly Asn Met Met Asp Trp Trp Ser Asn Phe Ser Thr Gln His  
 20 25 30  
 Phe Arg Glu Gln Ser Glu Cys Met Ile Tyr Gln Tyr Gly Asn Tyr Ser  
 35 40 45  
 Trp Asp Leu Ala Asp Glu Gln Asn Val Asn Gly Phe Asn Thr Leu Gly  
 50 55 60  
 Glu Asn Ile Ala Asp Asn Gly Gly Val Arg Gln Ala Tyr Lys Ala Tyr  
 65 70 75 80  
 Leu Lys Trp Met Ala Glu Gly Gly Lys Asp Gln Gln Leu Pro Gly Leu  
 85 90 95  
 Asp Leu Thr His Glu Gln Leu Phe Phe Ile Asn Tyr Ala Gln Val Trp  
 100 105 110  
 Cys Gly Cys Lys  
 115

<210> 5  
 <211> 20  
 <212> DNA  
 <213> artificial sequence  
 <223> oligonucleotide

<400> 5  
 TGGAGCGGCA GTTGGCTGTG

<210> 6  
<211> 21  
<212> DNA  
<213> artificial sequence  
<223> oligonucleotide

<400> 6  
AGTTCCCACT TGGGGCCCAT G

21

<210> 7  
<211> 20  
<212> DNA  
<213> artificial sequence  
<223> oligonucleotide

<400> 7  
GCTGGAGGAT TCCTCTGTCC

20

<210> 8  
<211> 19  
<212> DNA  
<213> artificial sequence  
<223> oligonucleotide

<400> 8  
CGGGGATCAC ATGGTGCCG

19

<210> 9  
<211> 21  
<212> DNA  
<213> artificial sequence  
<223> oligonucleotide

<400> 9  
CTACCCCAAG CTGCGTGATA G

21

<210> 10  
<211> 21  
<212> DNA  
<213> artificial sequence  
<223> oligonucleotide

<400> 10  
CGGCACCATG TGATCCCCGA G

21

<210> 11  
<211> 22  
<212> DNA  
<213> artificial sequence  
<223> oligonucleotide

<400> 11  
GCAAAGCACT AGCTTCAGTG TG

22

<210> 12  
<211> 22  
<212> DNA

**SECRET**

22

20

2.0

20

20

21

```
<210> 18
<211> 21
<212> DNA
<213> artificial sequence
<223> oligonucleotide
```





<210> 25  
<211> 26  
<212> DNA  
<213> artificial sequence  
<223> oligonucleotide

<400> 25  
ctgactgctc ccggaagtgc tgggtg 26

<210> 26  
<211> 18  
<212> DNA  
<213> artificial sequence  
<223> oligonucleotide

<400> 26  
gagcagctct tcttcac 18

<210> 27  
<211> 22  
<212> DNA  
<213> artificial sequence  
<223> oligonucleotide

<400> 27  
ctccaccaat ccatcatgtt gc 22

<210> 28  
<211> 6  
<212> PRT  
<213> artificial sequence  
<223> protein sequence corresponding to the oligonucleotide probe SEQ ID No. 22  
<400> 28

Glu Ile Thr His Phe Asp  
1 5

<210> 29  
<211> 6  
<212> PRT  
<213> artificial sequence  
<223> protein sequence corresponding to the oligonucleotide probe SEQ ID No. 23

<400> 29  
Gln Val Trp Cys Gly Ser  
1 5